iBio (NYSE:IBIO) Upgraded by StockNews.com to “Sell” Rating

StockNews.com upgraded shares of iBio (NYSE:IBIO) to a sell rating in a research note released on Tuesday morning.

iBio Stock Down 7.0 %

Shares of IBIO opened at $4.52 on Tuesday. The business’s 50-day moving average price is $3.85 and its 200-day moving average price is $2.92. iBio has a twelve month low of $1.05 and a twelve month high of $6.89. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05.

Insider Activity

In other iBio news, Director David Arkowitz acquired 18,382 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was bought at an average price of $2.72 per share, with a total value of $49,999.04. Following the completion of the acquisition, the director now owns 18,382 shares of the company’s stock, valued at $49,999.04. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in iBio stock. Geode Capital Management LLC lifted its holdings in shares of iBio, Inc. (NYSE:IBIO) by 52.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,797 shares of the company’s stock after purchasing an additional 28,775 shares during the quarter. Geode Capital Management LLC owned 0.85% of iBio worth $205,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.90% of the company’s stock.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.